Appointed
Matthew Pauls
Class I director
PVLA ·
PALVELLA THERAPEUTICS, INC.
appointed Matthew Pauls, to serve as a Class I director
Ready 8-Ks
50
Latest filing
June 30, 2026, 7:36 AM ET
Top materiality
0.95
Event mix
other_material ×30 · earnings ×9 · m_and_a ×4
Sentiment
13 pos · 9 neg · 28 neu
Latest earnings
▼ miss 2026-Q1
Executive change
recent →
Recent 8-K filings for PVLA
Highest-materiality recent filing
Palvella completes merger with Pieris, raises $78.9M PIPE, ticker changes to PVLA
- Merger closed Dec 13, 2024; Former Palvella survives as wholly-owned subsidiary; name changed to Palvella Therapeutics, Inc.
- PIPE financing raised $78.9M: $60.0M cash + conversion of $18.9M convertible notes; 3.17M shares and 2.47M pre-funded warrants issued.
-
Palvella Therapeutics appoints Matthew Pauls to Board of Directors
Board expanded from 7 to 8 members; Pauls appointed as Class I director effective June 29, 2026.
-
Palvella stockholders approve 750K-share increase to 2024 equity plan; re-elect three directors
Stockholders approved amendment to 2024 equity incentive plan, increasing authorized shares by 750,000. Votes: 7,692,709 for, 2,475,470 against.
-
Palvella Phase 3 SELVA: 100% of children responded; NDA filing on track for H2 2026
Phase 3 SELVA: 100% of 13 children (6-11 yrs) rated 'Much Improved' or better on mLM-IGA at Week 24 (mean +2.46, p<0.001).
-
Palvella reports Phase 2 TOIVA data: 100% bleed improvement, p=0.003
100% of patients with bleeding at baseline showed statistically significant improvement on cVM-IGA Bleeding at Week 12 (mean +2.5, p=0.003).
-
Palvella Therapeutics approved to uplist to Nasdaq Global Market on May 13
Nasdaq approval for transfer from Capital Market to Global Market received May 11, 2026.
-
Palvella Q1 net loss $15.8M; cash $261.9M after $230M equity raise; NDA on track H2 2026
Net loss $15.8M ($1.20/share) vs $8.2M ($0.74) in Q1 2025; R&D spend $9.3M up from $4.1M.
-
Palvella Therapeutics appoints John Doux, M.D. to Board of Directors
Board increased to 7 members; Dr. Doux appointed as Class III director with term expiring at 2026 Annual Meeting.
-
Palvella posts April 2026 corporate presentation; no material updates disclosed
Presentation titled 'First-in-disease therapies for patients with rare diseases'.
-
Palvella reports FY2025 net loss $41.7M; Phase 3 SELVA success paves path to NDA in H2 2026
Net loss $41.7M ($3.71 per share) vs $17.4M ($7.83) in FY2024; R&D $22.8M, G&A $15.8M.
-
Palvella Therapeutics raises ~$187.3M in public offering of 1.6M shares at $125/sh
Underwriting agreement with TD Securities, Cantor Fitzgerald, and Stifel for 1,600,000 shares at $125.00 each.
-
Palvella Therapeutics reports preliminary Dec 31, 2025 cash of $55.9M
Preliminary unaudited cash, cash equivalents and marketable securities as of Dec 31, 2025: $55.9 million.
-
Primary endpoint achieved: mean +2.13 improvement on mLM-IGA (p<0.001); all secondary endpoints met (p<0.001).
-
Topline data from Phase 3 SELVA study of QTORIN 3.9% rapamycin anhydrous gel for microcystic lymphatic malformations announced on Feb 24, 2026.
-
Palvella makes corporate presentation available; no new specifics disclosed
Presentation titled 'First-in-disease therapies for rare diseases' dated January 2026.
-
Palvella posts corporate presentation; no new disclosures
Corporate presentation posted on company website on January 12, 2026.
-
73% (11/15) improved on Overall cVM-IGA at Week 12; 67% rated "Much Improved" or "Very Much Improved".
-
Palvella Q3 net loss $11.3M; cash $63.6M; Phase 2/3 readouts on track for Dec 2025 and Q1 2026
Net loss per share $1.03 (basic/diluted) vs $3.94 a year ago; R&D expense rose to $6.5M.
-
Palvella announces QTORIN pitavastatin for DSAP; Phase 2 trial planned H2 2026
New candidate targets DSAP, a rare genetic skin disease with no FDA-approved therapies.
-
Palvella expands QTORIN rapamycin program into angiokeratomas, plans Phase 2 in H2 2026
No FDA-approved therapies exist for clinically significant angiokeratomas, which affect >50,000 diagnosed U.S. patients.
-
Palvella posts updated corporate presentation; no material new disclosures
Filed an 8-K under Item 7.01 furnishing a corporate presentation dated September 2025.
-
Palvella Q2 net loss $9.5M; Phase 3 LM trial enrollment exceeded target by 25%
Phase 3 SELVA enrolled 51 subjects (target 40); top-line results expected Q1 2026.
-
Palvella shareholders elect Heron, Wessel as Class II directors; ratify EY
Elaine J. Heron elected with 6,647,082 votes for, 1,255 withheld; Tadd S. Wessel with 6,487,034 for, 161,303 withheld.
-
Palvella Phase 3 SELVA enrollment surpasses target; cash $75.6M extends runway into H2 2027
Phase 3 SELVA for microcystic LM exceeded 40-patient enrollment; closes June 2025, top-line Q1 2026.
-
Palvella Therapeutics reports FY2024 net loss $17.4M, cash $83.6M; SELVA top-line Q1 2026 on track
Net loss $17.4M ($7.83/share) vs net income $17.9M in FY2023; R&D expense $8.2M, G&A $5.9M.
-
Company posted corporate presentation to website on March 4, 2025, for use in investor meetings.
-
Palvella posts corporate presentation for investor meetings; details not provided in filing
Filed under Item 7.01; corporate presentation posted to company website on Jan 13, 2025.
-
Palvella completes merger with Pieris, raises $78.9M PIPE, ticker changes to PVLA
Merger closed Dec 13, 2024; Former Palvella survives as wholly-owned subsidiary; name changed to Palvella Therapeutics, Inc.
-
Stockholders approve merger with Palvella; authorized shares increased 53x to 200M
Merger expected to close Dec. 13; pre-merger stockholders receive Contingent Value Rights.
-
Pieris supplements proxy for Palvella merger after 9 shareholder demands and 2 lawsuits
Annual meeting results: Kiritsy and Kiener elected directors; Ernst & Young ratified; say-on-pay approved.
-
Palvella (merger target of Pieris) awarded up to $2.6M FDA grant for Phase 3 rare skin disease trial
FDA Office of Orphan Products Development awarded Palvella up to $2.6M over 4 years to support Phase 3 SELVA trial of QTORIN rapamycin gel for microcystic lymphatic malformations.
-
Pieris issues special voting preferred to Chairman to secure authorized share increase vote
Issued 1 share of Series F Preferred to Chairman James Geraghty for $1 cash; preferred has 25M votes.
-
Pieris to merge with Palvella in all-stock deal; Palvella holders to own 82%; PIPE raises $78.9M
Merger values Pieris at ~$21M and Palvella at ~$95M; pre-PIPE, Pieris stockholders hold ~18% of combined company.
-
Pieris Pharmaceuticals' Servier collaboration terminated; S095012 Phase 1 halted on safety concern
Servier terminated license/collaboration agreement effective Dec 27, 2024, citing a potential safety concern in the S095012 Phase 1 study.
-
Pieris Pharmaceuticals regains compliance with Nasdaq minimum bid price rule
Received Nasdaq letter on May 7, 2024 confirming compliance with Listing Rule 5550(a)(2).
-
Pieris Pharmaceuticals announces 1-for-80 reverse stock split to regain Nasdaq compliance
Reverse stock split at ratio 1-for-80 effective 5:00 pm ET on April 22, 2024; begins trading split-adjusted on April 23 under symbol PIRS.
-
Pieris restructures to capture partnered milestones; ends R&D, cuts workforce, cash $26.4M
As of Dec 31, 2023, cash and investments $26.4M; cost cuts expected to extend runway into 2027.
-
Pieris terminates German lease; pays €9.7M to exit ~$22M remaining obligations
Lease termination effective Dec 31, 2023; fee of ~€9.7M paid to landlord.
-
Pieris adds $3.4M retention & severance costs to July 2023 restructuring estimate
Compensation Committee approved retention benefits for non-executive employees on Aug 30, 2023.
-
Pieris terminates AstraZeneca deal, cuts 70% workforce, explores strategic alternatives
AstraZeneca terminates R&D collaboration effective Oct 15, 2023 due to non-clinical safety findings in elarekibep toxicology study.
-
Chief Business Officer Ahmed Mousa resigns to become CEO of Vicore Pharma
Ahmed Mousa to resign as SVP, Chief Business Officer, General Counsel & Corporate Secretary effective September 11, 2023.
-
Stockholders approve 6M share increase under 2020 equity plan and adoption of 2023 ESPP
At June 21 annual meeting, stockholders approved amendment to 2020 equity incentive plan adding 6,000,000 shares.
-
AstraZeneca discontinues Phase 2a trial of elarekibep; lung findings from toxicology study
AstraZeneca ceases dosing in clinical studies of elarekibep (IL-4Rα inhibitor for asthma) due to lung pathology from a 13-week GLP toxicology study.
-
Pieris discontinues respiratory collaboration with Genentech for scientific reasons
Pieris and Genentech jointly ended the respiratory program in May 2023.
-
Pieris receives Nasdaq bid-price deficiency notice; 180-day cure period
Closing bid price below $1.00 for 30 consecutive business days triggers deficiency under Nasdaq Listing Rule 5550(a)(2).
-
Pieris Q1 net loss widens to $13.2M; elarekibep Phase 2a data expected mid-2024
Q1 2023 net loss of $13.2M ($0.45/share) vs. $5.1M ($0.07) in Q1 2022; cash $48.4M.
-
Net loss $33.3M ($0.45/share) vs $45.7M ($0.71) in 2021; R&D expense fell to $53.0M from $66.7M.
-
Pieris receives $5M milestone from Seagen for Phase 1 start of CD228 x 4-1BB bispecific SGN-BB228
Achieved $5M milestone from Seagen upon first patient dosed in Phase 1 study of SGN-BB228 (PRS-346).
-
Pieris Pharmaceuticals increases ATM offering capacity to $75M under amended Jefferies agreement
As of Nov 4, 2022, Pieris had sold $33.6M of stock under the prior $50M ATM program.
-
Pieris Q3 net loss $9.7M ($0.13/sh); cash at $69.8M, funded into Q2 2024
Net loss of $9.7M ($0.13 per share) vs $16.5M ($0.24) in Q3 2021.
-
Pieris doses first subject in Phase 1 trial of inhaled CTGF inhibitor PRS-220 for IPF
First subject dosed in Phase 1 dose-escalation study of PRS-220, an inhaled Anticalin protein targeting CTGF.
Executive changes
Departed
Shane Olwill
Senior Vice President and Chief Development Officer
PVLA ·
PALVELLA THERAPEUTICS, INC.
Pieris and Shane Olwill, Ph.D., Pieris’ Senior Vice President and Chief Development Officer, mutually agreed that in connection with the signing of the Merger Agreement, Dr. Olwill would step down effective October 31, 2024.
Departed
Ahmed Mousa
Senior Vice President, Chief Business Officer, General Counsel & Corporate Secretary
PVLA ·
PALVELLA THERAPEUTICS, INC.
On July 13, 2023, Ahmed Mousa, the Senior Vice President, Chief Business Officer, General Counsel & Corporate Secretary of Pieris Pharmaceuticals, Inc. (the “Company”), gave notice that he will resign from the Company effective September 11, 2023 in order to become chief executive officer of Vicore Pharma Holding AB.
Departed
Tim Demuth
Senior Vice President and Chief Medical Officer
PVLA ·
PALVELLA THERAPEUTICS, INC.
On August 4, 2022, Pieris Pharmaceuticals, Inc. (together with its wholly-owned subsidiary, Pieris Pharmaceuticals GmbH, the " Company ") announced that Tim Demuth, M.D., Ph.D. has mutually agreed with the Company to step down effective September 30, 2022 ("Separation Date").
Role change
Thomas Bures
Senior Vice President and Chief Financial Officer
PVLA ·
PALVELLA THERAPEUTICS, INC.
the Board appointed Mr. Thomas Bures, the Company’s Vice President, Finance and Treasurer, as Senior Vice President and Chief Financial Officer, effective as of October 6, 2021.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.95 · Median 0.65 · Most common event other_material